Max Robotics — Global Service Robot Directory + US Certification

About

S.A. Woodhouse is a leading clinical researcher in radiation oncology, whose work has fundamentally advanced the use of stereotactic body radiation therapy (SBRT) for prostate cancer. Their primary research focus is the radiobiology and clinical application of extreme hypofractionation—delivering very high doses of radiation in fewer, more intense sessions. Woodhouse’s major contribution is demonstrating that dose-escalated SBRT can be safely and effectively administered across multiple institutions, not just specialized centers. Their landmark 2018 multicenter trial, cited over 128 times, provided pivotal evidence on survival and toxicity endpoints for low- and intermediate-risk patients, establishing SBRT as a standard-of-care option. Woodhouse also pioneered the use of patient-reported quality-of-life outcomes, ensuring that treatment success is measured not just by tumor control but by the patient’s lived experience. Their 2016 five-year outcomes paper confirmed durable disease control, while their most recent 2023 work explores risk factors for late relapse, asking whether de-intensification is feasible for favorable subgroups. By bridging rigorous clinical trial design with patient-centered endpoints, Woodhouse has shaped modern prostate radiotherapy and inspired a generation of researchers to prioritize both efficacy and quality of life.